Arrowhead Pharmaceuticals FY 2026: Revenue $450.82M, EPS ($5.11) — 10-K Summary
Arrowhead Pharmaceuticals reported FY 2026 revenue of $450.82M, down 46% YoY, and a net loss of $724.21M, up 44302.6% YoY. The decline was attributed to lower collaboration revenue, offset partially by REDEMPLO sales and new partnerships. The company also incurred a $215M priority review voucher expense and increased R&D spending. Arrowhead launched REDEMPLO in the U.S. and received approvals in other regions, and advanced its plozasiran studies with positive Phase 3 results.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger a sell‑off in ARWR, with investors reassessing the company's reliance on partner revenues and the sizable voucher expense.
Market read
ARWR's earnings disappointment may influence biotech ETFs and peer stocks, but broader market impact is limited.
What to watch
Strong growth in REDEMPLO sales and new collaborations could offset the near‑term weakness.
Background
The article is an AI‑generated summary of Arrowhead Pharmaceuticals' FY 2026 10‑K filing, highlighting key financial metrics and pipeline updates.
Ticker impact
Arrowhead Pharmaceuticals reported FY 2026 revenue of $450.8M, a 46% YoY decline, and a net loss of $724.2M, highlighting weaker collaborations and a $215M voucher expense.
likely downward pressure as the market prices in weaker revenue and expanded loss
The 46% revenue drop and $215M voucher expense are material adverse factors for a biotech with a $450M revenue base.
Market effects
Biotech sector may see broader pressure as the results underscore reliance on partnership revenues.
U.S. biotech stocks could face short-term sell pressure.
Limited to investors tracking US-listed biotech earnings.
Counterpoint
If the company can successfully launch plozasiran in 2027, the current loss may be a temporary setback.
Key entities
- companyArrowhead Pharmaceuticals
US‑listed biotech (ticker ARWR) reporting FY 2026 results.
